Jesse Feierabend-Peters, MD, PhD and Hugh Silk, MD, MPH
Despite availability of good national oral health curricula for medical trainees, most physicians are ill-equipped to identify oral cancers or avoid unnecessary referrals.
AMA J Ethics. 2022;24(1):E19-26. doi:
10.1001/amajethics.2022.19.
Victoire Fokom Defo, MD and Joël Fokom Domgue, MD, MPH
HPV tests are alternatives to Pap smear screening that enable women to self-collect specimens and might be the best cervical cancer prevention strategy for many.
AMA J Ethics. 2020;22(2):E116-125. doi:
10.1001/amajethics.2020.116.
Dr Rajani Katta joins Ethics Talk to discuss her article, coauthored with Dina H. Zamil, Emily K. Burns, and Dr Ariadna Perez-Sanchez: “Do You Know How to Assess Risks Posed by Over-the-Counter Vitamin A Supplements?”
Annika Brakebill, A. Mark Fendrick, MD, and Jeffrey T. Kullgren, MD, MS, MPH
These key steps are ones health sector stakeholders should take to help patients and clinicians use pricing information to inform health decision making.
AMA J Ethics. 2022;24(11):E1034-1039. doi:
10.1001/amajethics.2022.1034.
Jing Li, PhD, Robert Tyler Braun, PhD, Sophia Kakarala, and Holly G. Prigerson, PhD
For dying patients and their loved ones to make informed decisions, physicians must share adequate information about prognoses, prospective benefits and harms of specific interventions, and costs.
AMA J Ethics. 2022;24(11):E1040-1048. doi:
10.1001/amajethics.2022.1040.
Aislinn C. Rookwood and Mariah Abney join Ethics Talk to discuss their article, coauthored with Hannah S. Butler-Robbins, Danielle Marie Westmark, and Dr Regina Idoate: “Arts-Based Research Methods to Explore Cancer in Indigenous Communities.”
Barriers to effective prognosis conversations include knowledge deficits, misconceptions, cultural differences, and lack of motivation. These can be addressed head-on by good communication interventions.
AMA J Ethics. 2018;20(8):E757-765. doi:
10.1001/amajethics.2018.757.
Thomas W. LeBlanc, MD, MA, MHS and Arif H. Kamal, MD, MBA, MHS
Clinical trials should assess patients’ distress and test interventions to address it, just as they assess adverse events and test novel therapeutic agents.
AMA J Ethics. 2017;19(5):460-466. doi:
10.1001/journalofethics.2017.19.5.stas1-1705.